标题
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
作者
关键词
Healthcare economics, pharmaceuticals, multiple sclerosis, disease modifying therapy
出版物
Neurotherapeutics
Volume 14, Issue 4, Pages 1018-1026
出版商
Springer Nature
发表日期
2017-08-16
DOI
10.1007/s13311-017-0566-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Financing and Distribution of Pharmaceuticals in the United States
- (2017) Matan C. Dabora et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending
- (2017) Stacie B. Dusetzina et al. JAMA Internal Medicine
- Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians
- (2016) Hilary Daniel et al. ANNALS OF INTERNAL MEDICINE
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States
- (2016) Aseel Bin Sawad et al. CURRENT MEDICAL RESEARCH AND OPINION
- Reducing costs while enhancing quality of care in MS: Table
- (2016) Ilya Kister et al. NEUROLOGY
- Multiple sclerosis prevalence in the United States commercially insured population
- (2016) Piyameth Dilokthornsakul et al. NEUROLOGY
- State Initiatives to Control Medication Costs — Can Transparency Legislation Help?
- (2016) Ameet Sarpatwari et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- Medicare payments to the neurology workforce in 2012
- (2015) L. E. Skolarus et al. NEUROLOGY
- The Patient Protection and Affordable Care Act and Chronic Neurological Illnesses
- (2015) Gregory J. Esper et al. JAMA Neurology
- Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis
- (2015) Dennis Bourdette et al. JAMA Neurology
- Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
- (2014) MerriKay Oleen-Burkey et al. BMC Neurology
- Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?
- (2014) David H. Howard NEW ENGLAND JOURNAL OF MEDICINE
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prescription-Drug Coupons — No Such Thing as a Free Lunch
- (2013) Joseph S. Ross et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cost burden of multiple sclerosis in the United States: a systematic review of the literature
- (2013) Gabriel Adelman et al. JOURNAL OF MEDICAL ECONOMICS
- Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
- (2013) Annie Hawton et al. Applied Health Economics and Health Policy
- Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US
- (2012) J. I. Ivanova et al. JOURNAL OF MEDICAL ECONOMICS
- Immune mechanisms of new therapeutic strategies in MS — Teriflunomide
- (2011) Malte C. Claussen et al. CLINICAL IMMUNOLOGY
- Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study
- (2011) K. Noyes et al. NEUROLOGY
- Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis
- (2010) Stephanie C. Steinberg et al. CLINICAL DRUG INVESTIGATION
- The changing demographic pattern of multiple sclerosis epidemiology
- (2010) Nils Koch-Henriksen et al. LANCET NEUROLOGY
- What Is Value in Health Care?
- (2010) Michael E. Porter NEW ENGLAND JOURNAL OF MEDICINE
- The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US
- (2010) Jasmina I. Ivanova et al. PHARMACOECONOMICS
- Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs
- (2010) Matthew W. Reynolds et al. JOURNAL OF MEDICAL ECONOMICS
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now